Physician profile
Suzanne Guynes
NPI 1700896313
$4,405.30
in general payments reported to CMS, 2019-2025
17 companies · $758 in 2025
The $758 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $406 · 2021: $1,274 · 2022: $507 · 2023: $201 · 2024: $234 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $603 · Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $603.44 |
| Food and Beverage | $590.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,482.76 | 2019-2022 | |
| Neuronetics, INC. | $758.46 | 2025 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $494.97 | 2020-2022 | |
| Abbvie INC. | $373.91 | 2021-2023 | |
| Allergan, INC. | $267.97 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $255.87 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $200.37 | 2019-2021 | |
| Noven Pharmaceuticals, INC. | $124.99 | 2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $109.01 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $101.32 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $74.16 | 2021 | |
| Vanda Pharmaceuticals INC. | $44.94 | 2020 | |
| Lundbeck LLC | $29.67 | 2022 | |
| Eisai INC. | $28.22 | 2020-2021 | |
| Almatica Pharma LLC | $23.90 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $19.61 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Guynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.